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injury
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Background: The aim of this study were to investigate whether selenium treatment attenuates lipid peroxidation
and downregulates the NF-κB pathway in small intestinal mucosa and to examine whether the effect of selenium is
also observed in oral buccal mucosa, during small intestinal IR injury.
Materials and methods: Eighteen rats were assigned into three groups: sham, IR, and IR + selenium. Saline or
selenium was administered through a tail vein. 24 hours later, the superior mesenteric artery was exposed and
clamped in the IR and IR + selenium groups. After ischemic and reperfusion period, animals were sacrificed and oral
buccal mucosa and small intestinal mucosa were harvested.
Results: Glutathione peroxidase activity and cytoplasmic IκB-α expression was higher in the IR + selenium group
than that in the IR group. A malondialdehyde level, cytoplasmic phosphorylated inhibitor κB-α, nuclear NF-κB p65
expressions, and NF-κB p65 DNA-binding activity were lower in the IR + selenium group than those in the IR group.
Conclusion: A selenium treatment may cause increased GPx activity, attenuated lipid peroxidation, and
downregulated the NF-κB pathway during small intestinal IR injury. Furthermore, these therapeutic benefits of
selenium can be observed in oral buccal mucosa as well as small intestinal mucosa.
Keywords: Ischemia reperfusion injury, Selenium, Lipid peroxidation, NF kappaB, Buccal mucosa, Small intestineIntroduction
When the blood supply diminishes in metabolically ac-
tive tissues, the tissue ischemia results in the so-called
ischemic injury. Subsequently, when the blood flow re-
stores, the reperfusion injury also occurs. This reperfusion
injury can damage the affected tissues more seriously than
the ischemic injury [1]. The development of reperfusion in-
jury is mediated by reactive oxygen species (ROS) forma-
tion, lipid peroxidation, and inflammatory responses [2].* Correspondence: suhgil@snu.ac.kr; omfs@chonbuk.ac.kr
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unless otherwise stated.Among the internal organs, the small intestine is the
most vulnerable organ to ischemia-reperfusion (IR) in-
jury [3]. IR injury in the small intestine breaks mucosal
barrier, which results in occurrence of systemic inflam-
matory response syndrome (SIRS). Then, SIRS can in-
duce secondary injuries to the distant organs leading to
multiple organ failure (MOF) or even to death [4]. The
mechanisms of the initiation and progression of SIRS
during small intestinal IR injury are ROS formation,
ROS-dependent inhibitor κB-α (IκB-α) phosphorylation
in cytoplasm, and subsequent nuclear factor κB (NF-κB)
activation in nucleus. Recent in vitro studies have shown
that ROS enhances cytoplasmic signaling pathways lead-
ing to NF-κB nuclear translocation [5-7]. Therefore, the
antioxidant therapy can be considered as a therapeutic
strategy to attenuate inflammatory responses induced by. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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suppressed NF-κB activation [8,9].
Selenium is an essential element having antioxidant
and immunomodulation function. Selenium is used to
synthesize the amino acid, called selenocysteine, which
is vital to the function of selenoprotein. At least, 25
selenoproteins are found in the human body and those
are classified by the function into antioxidant enzymes
(glutathione peroxidase, GPx), antioxidant proteins (sele-
noprotein P and W), other metabolic enzymes (thiore-
doxin reductase and iodine deiodinase) [10]. Previous
preclinical studies have reported that selenium suppresses
ROS formation by increasing GPx activity [11,12]. This
antioxidant effect could be responsible for the beneficial
effect of selenium such as inhibition of carcinogenesis,
myocardial protection in myocardial infarction, neuronal
protection in focal neurological injury [13,14]. Further-
more, some clinical studies showed that lower selenium
level was related with the increased mortality and the ad-
ministration of selenium (sodium selenite, Na2O3Se) has
improved the survival [15,16]. However, there have been
no in vivo studies which investigate therapeutic effects of
selenium on small intestinal IR injury.
The most accurate method to determine therapeutic
effects of selenium on small intestinal IR injury is to
examine the small intestine itself, which is clinically very
difficult. Oral buccal mucosa has the similar state of dif-
ferentiation to that of the small intestinal villi and shows
the decreased microvascular blood flow in distributive
shock [17-19]. Furthermore, oral buccal mucosa can be
easily and noninvasively accessible in clinical setting. If
oral buccal and small intestinal mucosal damages during
intestinal IR injury are similar, the oral buccal mucosa
can be considered as a marker for the evaluation of in-
testinal mucosal injury. In fact, our previous study was
conducted to determine the usefulness of oral buccal
mucosa in the evaluation of the intestinal IRI by estimat-
ing the activation level of the NF-кB pathway of the buccal
mucosa, and the result suggested a possibility of the buc-
cal mucosa as an indicator for the assessment of intestinal
ischemia-reperfusion injury [20]. Therefore, we hypothe-
sized that selenium pretreatment would enhance GPx
activity, attenuate lipid peroxidation, and downregulate
the NF-кB pathway by suppression of ROS formation and
subsequent ROS-dependent IκB-α phosphorylation during
small intestinal IR injury, and that antioxidant and anti-
inflammatory effects of selenium would be observed in
oral buccal mucosa as well as small intestinal mucosa.
The purpose of this study were to examine whether
selenium pretreatment is associated with the enhance-
ment of GPx activity, the suppression of ROS formation
and subsequent ROS-dependent IκB-α phosphorylation,
the attenuation of lipid peroxidation, and the downregu-
lation of the NF-кB pathway during small intestinal IRand to investigate if antioxidant and anti-inflammatory
effects of selenium are observed in oral buccal mucosa




Experiments were performed on male Sprague–Dawley
rats (body weight, 300 – 350 g; Orient Bio Incorporated,
Seongnam, Republic of Korea). Animals were maintained
on a laboratory chow (Lab Diet) and water ad libitum
and housed in a specific pathogen-free room at con-
stant temperature (20 - 22°C) with 10 and 14 hrs of
light and dark exposure, respectively. Animals under-
went an acclimatization period of 14 days before being
used in experiments. All of the experiments conducted
were approved by the Institutional Animal Care and
Use Committee of our institute.
Experimental procedure
Subjects were divided into the 3 groups (n = 6 in each
group): the sham group, animals of which underwent a
sham operation; the IR group, ischemic-reperfusion (IR)
injury alone; the IR + selenium group, IR injury plus selen-
ium infusion. Experimental procedures to induce IR injury
were performed as previously described [20]. Briefly, rats
were anesthetized with 100% oxygen and 3% Isoflurane
(Forane solution; Choongwae Pahrmacy, Seoul, Republic
of Korea) in the rodent circuit controller. Appropriate
level of anesthesia was obtained by intramuscular injection
of 15 mg/kg of Zoletil (zolazepam/tiletamine; Virbac
Labaratories, Carros cedex, France) in the femur of rats. A
midline incision was made in abdominal wall and the
superior mesenteric artery (SMA) was isolated without
any damage to the peritoneal organs and blood vessels. In
the IR and IR + selenium group, the isolated SMA was
clamped with a bulldog clamp. Adequate blockage of
SMA was confirmed by the color of the intestine turned
pale (please refer to the figure in our previous report) [20].
To minimize water and heat loss, abdominal muscle and
skin layers were then closed. After the 30 minutes of is-
chemic period, laparotomy was carried out again to
restore SMA blood flow. The bulldog clamp was re-
moved and reperfusion of the SMA was verified by the
scarlet color of the small intestine. Abdominal muscle
and skin layers were closed again. Then the animals
were returned to their cages and allowed food and water
ad libitum. All animals received 50 mg/kg of subcutane-
ous normal saline fluid after the procedures and no anti-
biotics were administered.
In the sham group, the clamping and declamping of
the SMA were not performed. The IR + selenium group
was administered selenium (60 μg/kg) and the sham and
IR group were administered saline vehicle through a tail
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administer selenium at 24 hours before intestinal IR in-
jury was based on the our previous study which showed
therapeutic benefits of selenium at 24 hours after admin-
istration in paraquat intoxicated rats [12].
After the 30 minutes of ischemic period and the
90 minutes of reperfusion period, animals were sacrificed
and oral buccal mucosa and small intestinal mucosa were
harvested. Oral buccal mucosa of rats was obtained from
both cheeks. Separated oral buccal mucosa and small
intestinal mucosa were washed with phosphate buffered
solution (PBS) for three times. After drying, those were
frozen and stored in liquid nitrogen tank at −70°C until
required. Blood samples obtained by cardiac puncture
were centrifuged at 2,000 g for 15 min at 4°C, and sepa-
rated sera were stored at −80°C for subsequent assays.
Measurements of GSH and GSSG levels, GPx activity, and
MDA level
Reduced glutathione (GSH) and oxidized glutathione
(GSSG) levels in oral buccal mucosa and small intestinal
mucosa were measured using a glutathione assay kit
(Cayman Chem. Ann Arbor, MI, USA) [21]. Glutathione
peroxidase (GPx) activity was measured using a gluta-
thione peroxidase assay kit (Cayman Chem). Malondial-
dehyde (MDA) level was fluorometrically measured as
2-thiobarbituric acid-reactive substance by the Ohkawa
method [22,23].
Nuclear and cytoplasmic extracts
The extraction of nuclear and cytoplasmic proteins from
oral buccal mucosa and small intestinal mucosa were
performed using a NEPER nuclear and cytoplasmic ex-
traction reagents kit (Pierce Chemical, Rockford, IL) [24].
Protein contents in the supernatant of the lysed mucosa
were determined using a BCA protein assay reagent kit
(Pierce Chemical).
Western blot analysis
To determine the expressions of cytoplasmic phosphor-
ylated IκB-α (p-IκB-α) and IκB-α and that of NF-κB
p65, we performed Western blotting as previously de-
scribed [24]. In brief, nuclear and cytoplasmic extracts
(10 μg per lane) were run on 8% and 12% sodium dodecyl
sulphate-polyacrylamide gels, respectively, and then trans-
ferred to polyvinylidene difluoride membranes (Schleicher
& Schuell, Dassel, Germany). The following primary anti-
bodies (Cell Signaling, Beverly, CA) were used for im-
munoblotting: rabbit antirat-p-IκB-α (1:250), IκB-α (1:500),
and NF-κB p65 (1:500) antibodies. As secondary anti-
bodies, antirabbit immunoglobulin G (Stressgen, Victoria,
BC, Canada) coupled with peroxidase and diluted 1:2000
in tris-buffered saline-Tween were used. Protein bands
were detected by an enhanced chemiluminescence (ECL)system (Amersham International, Buckinghamshire, UK).
Optical densities were quantified by a computer-assisted
densitometric analysis of the exposed films (Lap Work
Software; Seoulin Bioscience, Seoul, Republic of Korea). All
blots were normalized against β-actin to control for
protein loading. For β-actin measurements, the men-
tioned Western blot method was applied using a specific
mouse monoclonal anti-β-actin antibody (Sigma-Aldrich,
St.Louis, MO, USA).
NF-κB P65 DNA-binding activity
NF-κB p65 DNA-binding activity was determined using
the TransAM method, and a NF-κB p65 transcription
factor assay kit (Active Motif, Carlsbad, CA) was used to
detect and quantify NF-κB transcription factor activation
in oral buccal mucosa and small intestinal mucosa [25].
Enzyme-linked immunosorbent assay
Serum tumor necrosis factor-α (TNF-α) level was mea-
sured using Duoset enzyme-linked immunosorbent assay
kit (R&D System, Minneapolis, MN). Enzyme-linked
immunosorbent assay plates were measured using a
Versa Max microplate reader (Molecular Devices Corp,
Sunnyvale, CA) at 450 nm and concentrations of the re-
spective proteins in serum were calculated according to
calibration curves.
Statistical analysis
Data were analyzed by the Kruskal-Wallis with Mann–
Whitney U post hoc test and Bonferroni correction.
P-values of <0.017 were considered statistically signifi-
cant and the significance levels quoted are two-sided.
Statistical analysis was conducted using SPSS version
12.0 for Windows (SPSS, Chicago, IL).
Results
GSH and GSSG levels and GPx activity
There were no significant differences in GSH and GSSG
levels in oral buccal mucosa and small intestinal mucosa
between the IR and IR + selenium groups. In both the
oral buccal mucosa and small intestinal mucosa, how-
ever, GPx activity was higher in the IR + selenium group
than in the IR group (p = 0.004 and 0.002, respectively)
(Table 1).
MDA Level
In the IR + selenium group, MDA level was lower than
that in the IR group in both the oral buccal mucosa and
small intestinal mucosa (p = 0.004 and 0.002, respect-
ively) (Table 1).
Cytoplasmic p-IκB-α and IκB-α expressions
In the IR + selenium group, cytoplasmic p-IκB-α expres-
sion in oral buccal mucosa and small intestinal mucosa
Table 1 Laboratory results
N = 6/group. Median (range)
Small intestine Oral buccal mucosa
Sham IR IR + selenium Sham IR IR + selenium
GSH level (pmol/mg tissue) 460 (404–580) 400 (385–455) 401 (339–427) 509 (444–555) 468 (449–540) 448 (429–478)
GSSG level (pmol/mg tissue) 397 (322–457) 382 (348–419) 447✝(418–467) 387 (337–438) 354 (321–399) 392 (360–416)
GPx activity (mU/mg tissue) 3.06 (2.63-3.12) 2.72 (2.34-2.94) 3.47*✝(3.20-3.82) 3.26 (2.90-3.34) 2.60*(2.30-2.77) 2.90✝(2.76-3.16)
MDA level (pmol/mg tissue) 118 (110–134) 1113*(849–1258) 395*✝(178–471) 41 (21–58) 119*(106–134) 94*✝(48–108)
p-IκB-α expression (OD) 1.00 (0.53-1.28) 1.87*(1.49-2.50) 1.06✝(0.60-1.29) 0.23 (0.07-0.35) 1.45*(1.04-2.42) 0.52✝(0.31-0.83)
IκB-α expression (OD) 1.00 (0.88-1.28) 0.22*(0.12-0.44) 0.92✝(0.68-1.56) 0.48 (0.37-0.65) 0.20*(0.20-0.36) 0.48✝(0.32-0.58)
NF-κB p65 expression (OD) 1.00 (0.78-1.70) 17.40*(9.93-17.69) 3.77*✝(3.63-4.62) 0.33 (0.08-0.59) 8.44*(7.15-9.93) 2.32*✝(1.73-3.16)
NF-κB p65 DNA-binding (OD) 1.00 (0.90-1.23) 2.65*(1.80-2.93) 1.62*✝(1.20-2.03) 0.47 (0.47-0.50) 0.59*(0.54-0.67) 0.51✝(0.47-0.54)
Sham IR IR + selenium
Serum TNF-α level (pg/mL) 32.35 (31.08-34.90) 226.60 (183.46-330.04) 155.33 (129.01-203.32)
GSH, Reduced glutathione; GSSG, Oxidized glutathione; GPx, Glutathione peroxidase; MDA, Malondialdehyde; p-IκB-α, Phosphorylated inhibitor kappa B-α; NF-κB,
Nuclear factor kappa B; IR, Small intestinal ischemia-reperfusion injury; TNF-α, Tumor necrosis factor α.
*p <0.017 vs. the sham group. ✝p <0.017 vs. the ischemic-reperfusion injury (IR) group.
Kim et al. Journal of Inflammation 2014, 11:36 Page 4 of 8
http://www.journal-inflammation.com/content/11/1/36was lower than that in the IR group (p = 0.008 and 0.008,
respectively) (Figure 1). In contrast, cytoplasmic IκB-α
expression was higher in the IR + selenium group than
that in the IR group in both the oral buccal mucosa and
small intestinal mucosa (p = 0.016 and 0.008, respectively)
(Figure 1).
Nuclear NF-кB p65 expression
In the IR + selenium group, nuclear NF-кB p65 expres-
sion was lower than that in the IR group in both the oral
buccal mucosa and small intestinal mucosa (p = 0.008
and 0.008, respectively) (Figure 2).
NF-кB p65 DNA-binding activity
NF-кB p65 DNA-binding activity in oral buccal mucosa
and small intestinal mucosa was also lower in the IR +
selenium group than that in the IR group (p = 0.004 and
0.009, respectively) (Figure 3).
Serum TNF-α level
Serum TNF-α level in the IR + selenium group was sig-
nificantly lower than that in the IR group (p = 0.009)
(Figure 4).
Discussion
In the present study, we found that selenium pretreat-
ment increased GPx activity, attenuated lipid peroxida-
tion, downregulated the NF-κB pathway during small
intestinal IR injury. Previous in vitro experiments have
reported that oxidative stresses impair GPx to an in-
active form and GPx activity has a primary role in the
defense against oxidative stresses [26,27]. Our data also
showed that small intestinal IR injury suppressed GPx
activity and the increase of selenium-dependent GPxactivity by selenium treatment contributed to attenu-
ation of lipid peroxidation and downregulation of the
NF-κB pathway. Although the mechanisms of downreg-
ulation of the NF-κB pathway by selenium were not fully
determined in this study, we suggest that increased GPx
activity eliminates ROS and suppresses subsequent ROS-
dependent NF-κB activation. Since we did not use living
tissues but frozen tissues, we were not able to measure
ROS directly. We indirectly measured MDA level as a
substitute for ROS. MDA has been known as a marker
for lipid peroxidation by ROS. The decreased MDA
levels in selenium treated rats in this study might be
caused by the suppressed ROS formation, which support
our suggestion.
In the present study, selenium treatment did not alter
GSH or GSSG levels, which failed to show significant dif-
ferences between the IR and selenium treated IR groups.
Glutathione reductase reduces GSSG to GSH, and GPx
oxidized GSH to GSSG. No change of GSH or GSSG
levels in our study suggests that alternative mechanisms
may be related to maintain GSH level regardless of in-
creased GPx activity. Other previous data have shown that
an adaptive response to ROS results in producing an in-
crease in GSH level and the mechanism is associated with
recovery of glutathione reductase activity or increased ex-
pression of γ-glutamylcysteine synthase [28,29]. Further
studies which measure these enzymes will be needed to
confirm our data.
Small intestinal IR injury occurs in the various medical
conditions including necrotizing enterocolitis, midgut vol-
vulus, intussusception, mesenteric ischemic disease, small
bowel transplantation, aortic aneurysm surgery, cardio-
pulmonary bypass, hemodynamic shock, and sepsis. In
the present study, therapeutic benefits of selenium were
Figure 1 Cytoplasmic phosphorylated inhibitor κB-α (p-IκB-α) and IκB-α expressions in oral buccal mucosa and small intestinal mucosa.
Blots (a) are representative of the results of 6 rats per group. Normalized densities of p-IκB-α (b) and IκB-α (c) expressions. Data are median
(quatile, range). *p <0.017 vs. the sham group. ✝p <0.017 vs. the ischemic-reperfusion injury (IR) group.
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Figure 2 Nuclear NF-κB p65 expression in oral buccal mucosa and small intestinal mucosa. Blots are representative of the results of 6 rats
per group. Data are median (quatile, range). *p <0.017 vs. the sham group. ✝p <0.017 vs. the ischemic-reperfusion injury (IR) group.
Figure 3 NF-κB p65 DNA-binding activity in oral buccal mucosa
and small intestinal mucosa. Data are median (quatile, range).
*p <0.017 vs. the sham group. ✝p <0.017 vs. the ischemic-reperfusion
injury (IR) group.
Figure 4 Serum TNF-α level. Data are median (quatile, range).
*p <0.017 vs. the sham group. ✝p <0.017 vs. the ischemic-reperfusion
injury (IR) group.
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tinal mucosa. These results indicate that as a substitute for
the intestinal mucosa, oral buccal mucosa can be used to
detect the development of oxidative or inflammatory dam-
ages and to evaluate the beneficial effects of therapeutic
agents in critically ill patients with small intestinal IR
injury. In previous experimental data, we also found that
NF-κB pathway was upregulated in both the oral buccal
mucosa and the small intestinal mucosa during small intes-
tinal IR injury [20]. These data indicate that antioxidant
effects of selenium as well as oxidative stresses can be de-
termined in oral buccal mucosa during small intestinal IR
injury. However, the MDA level and NF-κB p65 DNA-
binding activity of small intestinal mucosa were higher
than those of oral buccal mucosa in the IR and selenium
treated IR groups. These data suggest that the development
of oral buccal mucosal injury is due to systemic inflamma-
tory responses rather than direct IR injury.
Recent meta-analysis data suggest that high dose of
selenium (>500 μg/day) may improve the outcomes
of critically ill patients, particularly dose at high risk of
death [30-33]. Clinical trials of selenium supplementa-
tion have used a wide range of doses. In several studies,
selenium was administered as an initial loading dose of
1000 – 2000 μg and thereafter a continuous infusion of
1000 – 1600 μg/day [16,34]. However, in two recent
large randomized controlled studies (RCT), 500–800 μg/
day of selenium were administered [35,36]. We infused a
single dose of selenium (60 μg/kg). This dose of selenium
in rats corresponds well to the doses used in the recent
RCTs [35,36]. Furthermore, the human dose can be trans-
lated to experimental dose in rat by the body surface area
normalization method [37,38]. The dose of selenium in
rat would then range from 48 to 77 μg/kg. Based on this
calculation, we selected a 60 μg/kg as a clinically relevant
dose. Clinically, it is so difficult to determine the adequate
timing of selenium administration after small intestinal IR
injury for the maximal antioxidant effect of selenium. The
present study shows that the GPx activities can be mea-
sured in oral buccal mucosa, directly. Before its clinical
use, further studies using more clinically relevant model
should be performed.
In the present study, the amount of tissues of oral buc-
cal mucosa was very small, and we failed to analyze tissue
directly. An additional set of experiment for morpho-
logical tissue analysis is needed to confirm our data.
Conclusion
Selenium enhanced glutathione peroxidase activity, at-
tenuated lipid peroxidation, and downregulated the NF-
κB pathway during small intestinal ischemic-reperfusion
injury. Furthermore, these therapeutic benefits of selen-
ium seem to be observed in oral buccal mucosa as well
as small intestinal mucosa.Abbreviations
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